In this issue:
Five-year survival with nivolumab + ipilimumab in advanced melanoma
Pembrolizumab vs ipilimumab in advanced melanoma
Response patterns in melanoma patients treated with ipilimumab + anti–PD-1
Targeted therapy in advanced melanoma with rare BRAF mutations
No survival benefit for CLND in patients with melanoma with positive SNL
Age favoured OS in metastatic melanoma treated with anti-PD1
ESMO Clinical Practice Guidelines for cutaneous melanoma
Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib
Survival with single vs multiple primary cutaneous melanomas
Prolonged OS following metastasectomy in stage IV melanoma
Please login below to download this issue (PDF)